Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

2.960 +0.120 (+4.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 435,471
Open 2.850
Bid (Size) 2.900 (1)
Ask (Size) 2.990 (50)
Prev. Close 2.840
Today's Range 2.840 - 2.980
52wk Range 1.960 - 5.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Humacyte to Present at the Cantor Global Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
From Humacyte, Inc
Via GlobeNewswire

Performance

YTD
+40.28%
+40.28%
1 Month
-21.59%
-21.59%
3 Month
-2.31%
-2.31%
6 Month
-2.95%
-2.95%
1 Year
-14.20%
-14.20%

More News

Read More
Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Via Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Humacyte Earnings Preview
Via Benzinga
Recap: Humacyte Q1 Earnings
Via Benzinga
Earnings Outlook For Humacyte
Via Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Earnings Preview For Humacyte
Via Benzinga
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
From Humacyte, Inc
Via GlobeNewswire
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
From Humacyte, Inc
Via GlobeNewswire
Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Via Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Humacyte Second Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Earnings Scheduled For August 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
Earnings Scheduled For May 12, 2023
Via Benzinga
Earnings Scheduled For March 24, 2023
Via Benzinga
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at Upcoming Investor Conferences in March
From Humacyte, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.